- Page 1 and 2:
Value through Innovation Annual Rep
- Page 3 and 4:
Contents 1 Value Through Innovation
- Page 5 and 6:
The Shareholders’ Perspective Dea
- Page 7 and 8:
Key Aspects of 2006 2006 was again
- Page 9 and 10:
This growth was clearly restrained
- Page 11 and 12:
Shareholders’ Committee Dr Heribe
- Page 13 and 14:
“There is help” “The woman wh
- Page 15 and 16:
1 continued from page 10 A Kenyan m
- Page 17 and 18:
1 Our people In pursuing our vision
- Page 19 and 20:
Company childcare enters new territ
- Page 21 and 22:
1 Caring for our neighbours We are
- Page 23 and 24:
0 Children from St Margaret Clither
- Page 25 and 26:
Our environment & employee safety A
- Page 27 and 28:
thanks to the use of the wood-fired
- Page 29 and 30:
Our goals We shall continue to inve
- Page 31 and 32:
Targeting tomorrow’s therapies Th
- Page 33 and 34:
0 continued from page 28 “Boehrin
- Page 35 and 36:
Our R & D strategy Research and dev
- Page 37 and 38:
Ridgefield, USA Cardiovascular, imm
- Page 39 and 40:
Vienna, Austria Oncology Boehringer
- Page 41 and 42:
Our expertise in landmark studies L
- Page 43 and 44:
From mind to man - the R & D proces
- Page 45 and 46:
New biological entities (NBE) One o
- Page 47 and 48:
The development of our businesses W
- Page 49:
Rin Fujima, Kyoto, Japan, suffers f
- Page 52 and 53:
Human Pharmaceuticals Branded presc
- Page 54 and 55:
cal exercise capacity and the reduc
- Page 56 and 57:
“Like a great round of golf“
- Page 58 and 59:
gives patients a better chance of g
- Page 60 and 61:
aptivus® was launched in the USA i
- Page 62 and 63:
enzymes, such as the HCV serine pro
- Page 64 and 65:
Børge Madsen, Copenhagen, Denmark.
- Page 66 and 67:
Cardiovascular diseases Despite sig
- Page 68 and 69:
actilyse® is the first and only th
- Page 70 and 71:
fibrillation in some 40 countries i
- Page 72 and 73:
Treatment modalities used to reliev
- Page 74 and 75:
HuCAL antibody directed against a c
- Page 76 and 77:
hand, the end of exclusivity in Eur
- Page 78 and 79:
Generic Prescription Medicines The
- Page 80 and 81:
Ben Venue - a world leader in steri
- Page 82 and 83:
Mara Lovera, Buenos Aires, Argentin
- Page 84 and 85:
Consumer Health Care Our Consumer H
- Page 86 and 87:
Switching reinforces the trend towa
- Page 88 and 89:
Alexander (left) and Christopher pl
- Page 90 and 91:
Animal Health The sound progress of
- Page 92 and 93:
located, trained and placed with fi
- Page 94 and 95:
Our Customer Orientation Our custom
- Page 96 and 97:
On a biopharmaceutical compound’s
- Page 98 and 99:
Pharmaceuticals Production Our Phar
- Page 100 and 101:
Counterfeits - a real threat for pa
- Page 102 and 103: Group Management Report 2006
- Page 104 and 105: companies lost their patent protect
- Page 106 and 107: To summarise, we see the success of
- Page 108 and 109: Production Production sites belongi
- Page 110 and 111: In the area of HIV/AIDS therapy, we
- Page 112 and 113: only 2 %. The region’s overall ne
- Page 114 and 115: of the cash flow, which rose by EUR
- Page 116 and 117: Report on expected developments The
- Page 118 and 119: Consolidated Financial Statements 2
- Page 120 and 121: C. H. Boehringer Sohn Grundstücksv
- Page 122 and 123: C. H. Boehringer Sohn, Ingelheim Co
- Page 124 and 125: C. H. Boehringer Sohn, Ingelheim St
- Page 126 and 127: The following subsidiaries were exe
- Page 128 and 129: 2 Accounting and evaluation methods
- Page 130 and 131: 3 Notes to the consolidated balance
- Page 132 and 133: 3.3 Financial assets (in millions o
- Page 134 and 135: Pension provisions Boehringer Ingel
- Page 136 and 137: 4 Notes to the consolidated profit
- Page 138 and 139: 4.7 Holding income (in millions of
- Page 140 and 141: Other mandatory disclosures accordi
- Page 142 and 143: Derivative financial instruments at
- Page 144 and 145: With the following exception, our a
- Page 146 and 147: Product name Active ingredient Indi
- Page 148 and 149: Product name Active ingredient Indi
- Page 150 and 151: Product name Active ingredient Indi
- Page 154 and 155: Product name Active ingredient Indi
- Page 156 and 157: Comparison of Balance Sheets/ Finan